Lyell Immunopharma, INC Schedule 13G passive stakes

Innovative Cellular Therapeutics Holdings Limited has increased its beneficial ownership in Lyell Immunopharma, Inc. to 12.3% following the achievement of a development milestone.

ARCH Venture Partners and affiliated entities have reported a 13.9% beneficial ownership stake in Lyell Immunopharma, Inc.

MWG Caph Ltd and Milky Way Investments Group Ltd report a combined 4.3% stake in Lyell Immunopharma, Inc. as of March 31, 2026.

Explore Investments LLC and Jeffrey P. Bezos have filed a Schedule 13G reporting a 6.6% beneficial ownership stake in Lyell Immunopharma, Inc.

Euler Fund, L.P., along with its general partner Euler Managers Limited and indirect owner Antonis Indianos, has disclosed beneficial ownership of 1,426,528 shares, representing 6.71% of Lyell Immunopharma, Inc.'s common stock.

ARCH Venture Funds and associated individuals collectively report a 13.0% beneficial ownership in Lyell Immunopharma, Inc. common stock.

Foresite Capital and its affiliates, led by James Tananbaum, reported a combined beneficial ownership of 7.6% in Lyell Immunopharma, Inc. as of September 30, 2025.

Innovative Cellular Therapeutics Holdings Ltd has reported a 9.8% beneficial ownership stake in Lyell Immunopharma, Inc., totaling 1.9 million shares.

Newton (PTC) Limited and affiliated entities have reduced their beneficial ownership in Lyell Immunopharma, Inc. to 3.93%.

Explore Investments LLC, controlled by Jeffrey P. Bezos, has reported a 5.4% passive beneficial ownership stake in Lyell Immunopharma, Inc.

Gates Frontier, LLC and William H. Gates III have jointly reported a beneficial ownership of 5.6% in Lyell Immunopharma, Inc., totaling 1,040,964 shares of common stock.

Foresite Capital entities and managing member James Tananbaum have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.2% of Lyell Immunopharma, Inc.'s common stock as of March 31, 2025.

ARCH Venture Fund entities and their managing directors have reported a combined passive beneficial ownership of 13.1% in Lyell Immunopharma, Inc. as of December 31, 2024.

Foresite Capital and its affiliated funds, including James Tananbaum, have filed an amended Schedule 13G disclosing a combined passive beneficial ownership of 6.7% in Lyell Immunopharma, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G indicating its beneficial ownership in Lyell Immunopharma, Inc. has decreased to 4.5% as of December 31, 2024.